

optionally including a pharmacologically acceptable complexing agent, stabilizer, a pharmacologically acceptable cosolvent, or other pharmacologically acceptable adjuvants and additives.--

--54. (New) The pharmaceutical preparation according to claim 53, wherein the tiotropium salt is a salt formed with HBr, HCl, HI, monomethylsulfuric acid ester, methanesulfonic acid, or *p*-toluenesulfonic acid.--

--55. (New) The pharmaceutical preparation according to claim 53, wherein the tiotropium salt is tiotropium bromide.--

--56. (New) The pharmaceutical preparation according to claim 53, wherein the tiotropium salt is tiotropium bromide monohydrate.--

--57. (New) The pharmaceutical preparation according to claim 53, wherein the solvent is water.--

--58. (New) The pharmaceutical preparation according to claim 54, wherein the solvent is water.--

--59. (New) The pharmaceutical preparation according to claim 55, wherein the solvent is water.--

--60. (New) The pharmaceutical preparation according to claim 56, wherein the solvent is water.--

--61. (New) The pharmaceutical preparation according to claim 53, wherein the solvent is a water-ethanol mixture with up to 70 vol.% of ethanol.--

--62. (New) The pharmaceutical preparation according to claim 54, wherein the solvent is a water-ethanol mixture with up to 70 vol.% of ethanol.--

--63. (New) The pharmaceutical preparation according to claim 55, wherein the solvent is a water-ethanol mixture with up to 70 vol.% of ethanol.--

--64. (New) The pharmaceutical preparation according to claim 56, wherein the solvent is a water-ethanol mixture with up to 70 vol.% of ethanol.--

--65. (New) The pharmaceutical preparation according to claim 61, wherein the solvent is a water-ethanol mixture with up to 60 vol.% of ethanol.--

--66. (New) The pharmaceutical preparation according to claim 65, wherein the solvent is a water-ethanol mixture with up to 30 vol.% of ethanol.--

--67. (New) The pharmaceutical preparation according to one of claims 53 to 56, wherein the pharmaceutical preparation does not contain a complexing agent.--

--68. (New) The pharmaceutical preparation according to one of claims 53 to 56, wherein the pharmaceutical preparation does not contain a stabilizer.--

--69. (New) The pharmaceutical preparation according to one of claims 53 to 56, wherein edetic acid salt is present in an amount of greater than 0 up to 25 mg/100 ml.--

--70. (New) The pharmaceutical preparation according to claim 69, wherein the edetic acid salt is sodium edetate.--

--71. (New) The pharmaceutical preparation according to one of claims 53 to 56, wherein the pH is between 2.5 and 3.5.--

--72. (New) The pharmaceutical preparation according to claim 71, wherein the pH is between 2.7 and 3.3.--

--73. (New) The pharmaceutical preparation according to one of claims 53 to 56, wherein the concentration based on tiotropium is between 0.001% and 3% by weight.--

--74. (New) The pharmaceutical preparation according to claim 73, wherein the concentration based on tiotropium is between 0.0005% to 0.5% by weight.--

--75. (New) The pharmaceutical preparation according to claim 74, wherein the concentration based on tiotropium is between 0.0005% to 0.25% by weight.--

--76. (New) The pharmaceutical preparation according to claim 75, wherein the concentration based on tiotropium is between 0.001% to 0.1% by weight.--

--77. (New) The pharmaceutical preparation according to one of claims 53 to 56, wherein the pharmacologically acceptable preservative is benzalkonium chloride.--

--78. (New) The pharmaceutical preparation according to one of claims 53 to 56, wherein the pharmaceutical preparation comprises a pharmacologically acceptable adjuvant or additive.--

--79. (New) The pharmaceutical preparation according to claim 78, wherein pharmacologically acceptable adjuvant or additive is an antioxidant.--

--80. (New) The pharmaceutical preparation according to one of claims 53 to 56, wherein the pharmaceutical preparation contains no cosolvents and/or pharmacologically acceptable adjuvants and additives apart from the preservative.--

81. (New) A method for administering a pharmaceutical preparation according to one of claims 53 to 56, comprising nebulizing the pharmaceutical preparation in an inhaler selected from the group consisting of: (a) an inhaler according to WO 91/14468, or (b) an inhaler according to Figures 6a and 6b of WO 97/12687.--

--82. (New) A method for administering a pharmaceutical preparation according to one of claims 53 to 56, comprising nebulizing the pharmaceutical preparation in an inhaler which nebulizes defined amounts of the pharmaceutical preparation by the application of pressures from 100 to 600 bar through a nozzle having at least one nozzle opening with a depth of 2 to 10 microns and a width of 5 to 15 microns to form an inhalable aerosol.--

--83. (New) The method according to claim 82, wherein at least one nozzle opening is at least two nozzle openings which are inclined relative to one another in the direction of the nozzle opening at an angle of from 20 degrees to 160 degrees.--

--84. (New) The method according to claim 82, wherein the defined amounts of the pharmaceutical preparation are 10 to 50 microliters.--

--85. (New) The method according to claim 81, wherein the inhaler is 9 cm to 15 cm long and 2 cm to 4 cm wide.--

--86. (New) The method according to claim 82, wherein the inhaler is 9 cm to 15 cm long and 2 cm to 4 cm wide.--

--87. (New) The method according to claim 81, wherein the mass of pharmaceutical formulation delivered in at least 97% of all actuations of the inhaler is between 5 mg and 30 mg within a range of tolerance of 25%.--

--88. (New) The method according to claim 82, wherein the mass of pharmaceutical formulation delivered in at least 97% of all actuations of the inhaler is between 5 mg and 30 mg within a range of tolerance of 25%.--

--89. (New) The method according to claim 81, wherein the mass of pharmaceutical formulation delivered in at least 97% of all actuations of the inhaler is between 5 mg and 30 mg within a range of tolerance of 20%.--

--90. (New) The method according to claim 82, wherein the mass of pharmaceutical formulation delivered in at least 97% of all actuations of the inhaler is between 5 mg and 30 mg within a range of tolerance of 20%.--

--91. (New) The method according to claim 81, wherein the mass of pharmaceutical formulation delivered in at least 98% of all actuations of the inhaler is between 5 mg and 30 mg within a range of tolerance of 20%.--

--92. (New) The method according to claim 82, wherein the mass of pharmaceutical formulation delivered in at least 98% of all actuations of the inhaler is between 5 mg and 30 mg within a range of tolerance of 20%.--

--93. (New) A method of treating asthma or COPD in a patient, the method comprising administering to the patient a pharmaceutical preparation according to one of claims 53 to 56.--

AI --94. (New) A method of treating asthma or COPD in a patient, the method comprising administering to the patient a pharmaceutical preparation using the method of claim 81.--

--95. (New) A method of treating asthma or COPD in a patient, the method comprising administering to the patient a pharmaceutical preparation using the method of claim 82.--

---